Zonisamide

Medical uses

Epilepsy

Zonisamide is approved in the United States, and United Kingdom for adjunctive treatment of partial seizures in adults and Japan for both adjunctive and monotherapy for partial seizures (simple, complex, secondarily generalized), generalized (tonic, tonic-clonic (grand mal), and atypical absence) and combined seizures. In Australia it is marketed as both an adjunctive therapy and monotherapy for partial seizures only.

Parkinson's disease

It has been approved for the treatment of the motor symptoms of Parkinson's disease (PD), as an adjunct to levodopa, in a few countries such as Japan. In Japan, zonisamide has been used as an adjunct to levodopa treatment since 2009. In addition, there is clinical evidence that zonisamide in combination with levodopa control of motor symptoms of PD but evidence for the treatment of the non motor symptoms of PD lacking.

Adverse effects

Adverse effects by incidence:

Very common (10% incidence) adverse effects include:

• Anorexia
• Somnolence
• Dizziness
• Agitation
• Irritability
• Confusional state
• Depression
• Diplopia
• Memory impairment
• Decreased bicarbonate

Common (1–10% incidence) adverse effects include:

• Ecchymosis
• Hypersensitivity
• Affect lability
• Anxiety
• Insomnia
• Psychotic disorder
• Bradyphrenia
• Disturbance in attention
• Nystagmus
• Paraesthesia
• Speech disorder
• Tremor
• Abdominal pain
• Constipation
• Diarrhoea
• Dyspepsia
• Nausea
• Rash
• Pruritus
• Alopecia
• Nephrolithiasis
• Fatigue
• Influenza-like illness
• Pyrexia
• Oedema peripheral
• Weight loss

Incidence unknown

• Reproductive toxic effects

Interactions

Zonisamide and other carbonic anhydrase inhibitors such as topiramate, furosemide, and hydrochlorothiazide have been known to interfere with amobarbital, which has led to inadequate anesthetization during the Wada test. Zonisamide may also interact with other carbonic anhydrase inhibitors to increase the potential for metabolic acidosis.

Additionally, the metabolism of zonisamide is inhibited by ketoconazole, ciclosporin, miconazole, fluconazole and carbamazepine (in descending order of inhibition) due to their effects on the CYP3A4 enzyme.

Zonisamide is not known to inhibit cytochrome P450 enzymes when present at therapeutic concentrations.

Mechanism of action

Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and T-type calcium channels, which leads to the suppression of neuronal hypersynchronization (that is, seizure-form activity). More recently, it has also been demonstrated to positively modulate cerebral glycine receptors.

Pharmacokinetics

Absorption

Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8–3.9 hours. Bioavailability is close to 100% and food has no effect on the bioavailability of zonisamide but may affect the rate of absorption.

Metabolism

Zonisamide is metabolized mostly by the CYP3A4 isoenzyme, but also CYP3A7 and CYP3A5, to 2-(sulphamoylacetyl)-phenol via reductive cleavage of the 1,2-benzisoxazole ring.

History

Zonisamide was discovered by Uno and colleagues in 1972 and launched by Dainippon Sumitomo Pharma (formerly Dainippon Pharmaceutical) in 1989 as Excegran in Japan. It was marketed by Élan in the United States starting in 2000 as Zonegran, before Élan transferred their interests in zonisamide to Eisai Co., Ltd. in 2004. Eisai also markets Zonegran in Asia (China, Taiwan, and fourteen others) and Europe (starting in Germany and the United Kingdom).

Research

Tardive dyskinesia

In an open-label trial zonisamide attenuated the symptoms of tardive dyskinesia.

Obesity

It has also been studied for obesity with significant positive effects on body weight loss and there are three ongoing clinical trials for this indication. It was to be sold, when combined with bupropion, under the brand name Empatic, until its development was discontinued.

Migraine

Zonisamide has been studied for and used as a migraine preventative medication, when topiramate is either ineffective or cannot be continued due to side effects.

Bipolar depression

It has also been used off-label by psychiatrists as a mood stabilizer to treat bipolar depression.

References

References

1. (21 June 2022). "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017".
2. (20 August 2021). "Zonegran- zonisamide capsule".
3. (15 July 2022). "Zonisade- zonisamide suspension".
4. (10 March 2005). "Zonegran EPAR".
5. (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology.
6. (8 March 2016). "Zonisamide: Martindale: The Complete Drug Reference". Pharmaceutical Press.
7. (2007). "Comprehensive Pharmacy Review". Williams & Wilkins.
8. "The Top 300 of 2020".
9. "Zonisamide - Drug Usage Statistics".
10. (24 December 1999). "Drug Approval Package: Zonegran (Zonisomide) NDA #20-789".
11. Eisai Ltd.. (2005). "Zonegran Summary of Product Characteristics". Medicines.org.uk.
12. Dainippon Pharmaceutical Co., Ltd.. (2004). "EXCEGRAN Tablets 100 mg & EXCEGRAN Powder 20%".
13. (January 2007). "Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study". Neurology.
14. (2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology.
15. (2017). "Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis". Journal of Alzheimer's Disease.
16. (4 April 2013). "Zonegran Product Information". SciGen (Australia) Pty Ltd.
17. (8 October 2013). "Zonegran 25, 50, 100 mg Hard Capsules". Eisai Ltd.
18. "zonisamide (Rx) - Zonegran". WebMD.
19. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology.
20. (February 2005). "Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications". Epilepsia.
21. (April 1998). "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data". European Journal of Clinical Pharmacology.
22. "Zonegran 25, 50, 100 mg Hard Capsules". Electronic Medicines Compendium (eMC).
23. (2013). "Australian Medicines Handbook". The Australian Medicines Handbook Unit Trust.
24. (December 2004). "Zonisamide: chemistry, mechanism of action, and pharmacokinetics". Seizure.
25. (March 1990). "Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain". Medical Journal of Osaka University.
26. (March 1990). "[3H]zonisamide binding in rat brain". Medical Journal of Osaka University.
27. (August 2003). "Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures". Brain Research. Molecular Brain Research.
28. (January 2021). "The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations". Neuropharmacology.
29. "Zonisamide".
30. (May 1998). "Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells". Biochimica et Biophysica Acta (BBA) - General Subjects.
31. (January 1992). "Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative". Xenobiotica.
32. (2002-06-15). "Antiepileptic Drugs". Lippincott Williams & Wilkins.
33. Dainippon Sumitomo Pharma Co. Ltd.. (2005). "Company History". Dainippon Sumitomo Co., Ltd..
34. Dainippon Pharmaceutical Co. Ltd.. (2004). "Transfer of Rights Agreement for North America and Europe Reached on Zonegran". Dainippon Sumitomo Pharma Co., Ltd.
35. Dainippon Pharmaceutical Co. Ltd.. (2005). "Dainippon Pharmaceutical and Eisai Conclude Agreement for the Development, Manufacture and Marketing of the Anti-Epileptic Agent Zonisamide in Asia". Dainippon Sumitomo Pharma Co., Ltd..
36. Eisai Co. Ltd.. (2005). "Eisai Announces Launch of Zonegran (zonisamide), Treatment For Epilepsy In the UK and Germany". Eisai Co., Ltd..
37. (April 2012). "Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial". Journal of the Neurological Sciences.
38. (April 2003). "Zonisamide for weight loss in obese adults: a randomized controlled trial". JAMA.
39. University of Cincinnati. (2005). "Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity". ClinicalTrials.gov.
40. (2005). "Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial". ClinicalTrials.gov.
41. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2006). "Zonisamide for Weight Reduction in Obese Adults". ClinicalTrials.gov.
42. (20 May 2017). "Bupropion/zonisamide". Springer.
43. (2004). "Zonegran".
44. (May 2004). "Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital". Current Medical Research and Opinion.